Arrowhead Pharmaceuticals (ARWR) Current Leases (2011 - 2026)

Arrowhead Pharmaceuticals (ARWR) has 14 years of Current Leases data on file, last reported at $7.8 million in Q1 2026.

• Quarterly Current Leases rose 14.63% year-over-year to $7.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.8 million (up 14.63% YoY) and the FY2025 annual result came in at $7.3 million, up 14.93% from the prior year.
• Current Leases advanced to $7.8 million in Q1 2026, from $7.5 million in the prior quarter.
• In the past five years, Current Leases ranged from a high of $10.6 million in Q3 2023 to a low of $2.7 million in Q4 2022.
• A 5-year average of $5.4 million and a median of $6.1 million in 2024 frame the typical range for Current Leases.
• Annual changes were most pronounced in 2023 — Current Leases soared 280.51% — and 2024, when it slumped 39.96%.
• Tracing ARWR's Current Leases over 5 years: stood at $2.7 million in 2022, then climbed by 28.42% to $3.4 million in 2023, then soared by 91.76% to $6.6 million in 2024, then advanced by 14.77% to $7.5 million in 2025, then advanced by 3.25% to $7.8 million in 2026.
• The last three Current Leases figures came in at $7.8 million (Q1 2026), $7.5 million (Q4 2025), and $7.3 million (Q3 2025), per Business Quant data.